Determinación del panel de inmunohistoquímica más útil para el diagnóstico de certeza de las neoplasias mesenquimatosas malignas de tejidos blandos.

Introduction: Malignant mesenchymal neoplasms tumors with great local and metastatic destructive effects. Immunohistochemistry (IHC) antibodies of recent appearance are currently available that can support the diagnosis of certainty. Objective: To evaluate the usefulness of IHC as an auxiliary tool for the diagnosis of certainty of these neoplasms; determining its prevalence and age distribution in our population. Material and methods: Observational, ambispective, cross-sectional and descriptive study, collected the histopathological diagnoses of malignant mesenchymal malignancies of soft tissues emitted in the Department of Pathological Anatomy from January 2012 to June 2017. IHC antibodies were performed (MDM-2, CDK-4, TLE-1, MUC-4 and SOX-10) in different sarcomas to determine its diagnostic utility. Results: 110 cases were collected, in 54 evaluated with MDM-2 and CDK-4 greater specificity was observed in liposarcomas, nine synovial sarcomas with TLE-1 with positivity of 100% in all cases, four malignant tumors of nerve sheath with SOX-10 and S-100 confirming utility in the diagnosis. Conclusions: IHC is a useful tool for the diagnosis of malignant mesenchymal neoplasms, since it gives lines of differentiation in specific tumors that help to guide the pathologist towards a diagnosis of certainty. [ABSTRACT FROM AUTHOR]